Verzenio

Active Ingredient(s): Abemaciclib
FDA Approved: * September 28, 2017
Pharm Company: * ELI LILLY AND CO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Verzenio Overview

Abemaciclib (trade name Verzenio) is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.[1] It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration (FDA) in October 2015.[2] On 28 September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers.[3&...

Read more Verzenio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Abemaciclib

Recent Verzenio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Abemaciclib
  • Tablet: 100mg, 150mg, 200mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Verzenio: (4 results)

Sorted by National Drug Code
  • 0002-4483 Verzenio 50 mg Oral Tablet by Eli Lilly and Company
  • 0002-4815 Verzenio 100 mg Oral Tablet by Eli Lilly and Company
  • 0002-5337 Verzenio 150 mg Oral Tablet by Eli Lilly and Company
  • 0002-6216 Verzenio 200 mg Oral Tablet by Eli Lilly and Company

Other drugs which contain Abemaciclib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA